Evolut showed less bioprosthetic valve dysfunction, prosthetic valve thrombosis and haemodynamic structural valve dysfunction ...
Patients with symptomatic severe aortic stenosis undergoing CoreValve or Evolut TAVI have better 5-year bioprosthetic valve ...
A study led by bioengineers at the University of California San Diego sheds new light on how a type of heart valve disease, called aortic valve stenosis, progresses differently in males and females.
Recent research from Karl Landsteiner University of Health Sciences (KL Krems) provides important new insights into how ...
Laplace Interventional, a US-based medical device company focusing on transcatheter valve technology, recently announced the ...
The following is a summary of "Transcatheter Aortic Valve Replacement Beyond Severe Aortic Stenosis: JACC State-of-the-Art ...
A novel therapeutic showed significant promise in slowing aortic valve calcification, potentially extending time until or eliminating need for transcatheter or surgical intervention for stenosis, ...
The data raise questions about valve hemodynamics and the role of early imaging to stay ahead of clinical and subclinical ...
Partial heart transplants provide a range of lifesaving options for children with complex congenital heart conditions, and can lead to a domino effect of life-saving procedures.
Medical Device Network on MSN10d
Medtronic announces two-year trial outcomes of Evolut TAVRMedtronic has announced the SMART trial’s two-year outcomes of Evolut TAVR for aortic stenosis (AS) and small aortic annulus.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback